Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer

0Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the efficacy and safety of the use of anti-angiogenic agents (VEGF inhibitors) in the adjuvant setting after resection in patients diagnosed with resectable colorectal cancer. This would permit a summary of the safety and effectiveness of anti-VEGF therapies overall, as well as in pre-planned prognostic subgroups, and identify areas where further research could be directed.

Cite

CITATION STYLE

APA

Chan, D. L. H., Espinoza, D., Chan, J., Lee, A., Faisal, W., Segelov, E., & Pavlakis, N. (2016). Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. Cochrane Database of Systematic Reviews, 2016(12). https://doi.org/10.1002/14651858.CD012460

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free